Literature DB >> 2997301

Immunoreactive corticotropin-releasing factor in human plasma.

T Suda, N Tomori, F Yajima, T Sumitomo, Y Nakagami, T Ushiyama, H Demura, K Shizume.   

Abstract

Plasma immunoreactive corticotropin-releasing factor (I-CRF) levels were determined by using a human CRF radioimmunoassay and an immunoaffinity procedure. The basal plasma I-CRF level in normal subjects was 6 +/- 0.5 pg/ml (mean +/- SD). We found that most plasma I-CRF levels were affected by stress, negative feedback, and circadian rhythm. Basal I-CRF levels were high in patients with Addison's disease, Nelson's syndrome, hypopituitarism stemming from pituitary macroadenoma, and CRF- and adrenocorticotropic hormone-producing tumors. A very low, but significant, amount of I-CRF was detected (1-3 pg/ml) in patients with Cushing's syndrome, in corticosteroid-treated patients, and in a patient with hypothalamic hypopituitarism. These results suggest that a major component of plasma I-CRF is of hypothalamic origin, however, other extrahypothalamic tissues cannot be ruled out as a minor source of plasma I-CRF.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2997301      PMCID: PMC424270          DOI: 10.1172/JCI112204

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  Human plasma immunoreactive lipotropin and adrenocorticotropin in normal subjects and in patients with pituitary-adrenal disease.

Authors:  D T Krieger; A S Liotta; T Suda; A Goodgold; E Condon
Journal:  J Clin Endocrinol Metab       Date:  1979-04       Impact factor: 5.958

2.  A fundamental defect of adrenocortical control in Cushing's disease.

Authors:  V H James; J Landon; V Wynn; F C Greenwood
Journal:  J Endocrinol       Date:  1968-01       Impact factor: 4.286

3.  Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin.

Authors:  W Vale; J Spiess; C Rivier; J Rivier
Journal:  Science       Date:  1981-09-18       Impact factor: 47.728

4.  Effect of synthetic ovine corticotropin-releasing factor. Dose response of plasma adrenocorticotropin and cortisol.

Authors:  D N Orth; R V Jackson; G S DeCherney; C R DeBold; A N Alexander; D P Island; J Rivier; C Rivier; J Spiess; W Vale
Journal:  J Clin Invest       Date:  1983-03       Impact factor: 14.808

5.  Presence of corticotropin releasing factor-like immunoreactivity in hypophysial portal blood.

Authors:  D M Gibbs; W Vale
Journal:  Endocrinology       Date:  1982-10       Impact factor: 4.736

6.  Characterization of rat hypothalamic corticotropin-releasing factor.

Authors:  J Rivier; J Spiess; W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  1983-08       Impact factor: 11.205

7.  Corticotropin releasing factor (CRF): immunoreactive neurones and fibers in rat hypothalamus.

Authors:  F E Bloom; E L Battenberg; J Rivier; W Vale
Journal:  Regul Pept       Date:  1982-06

8.  Presence of immunoreactive corticotropin-releasing factor in human cerebrospinal fluid.

Authors:  T Suda; F Tozawa; T Mouri; H Demura; K Shizume
Journal:  J Clin Endocrinol Metab       Date:  1983-07       Impact factor: 5.958

9.  Distribution and characterization of immunoreactive corticotropin-releasing factor in human tissues.

Authors:  T Suda; N Tomori; F Tozawa; T Mouri; H Demura; K Shizume
Journal:  J Clin Endocrinol Metab       Date:  1984-11       Impact factor: 5.958

10.  Effects of bilateral adrenalectomy on immunoreactive corticotropin-releasing factor in the rat median eminence and intermediate-posterior pituitary.

Authors:  T Suda; N Tomori; F Tozawa; T Mouri; H Demura; K Shizume
Journal:  Endocrinology       Date:  1983-09       Impact factor: 4.736

View more
  13 in total

1.  Coexistence of hypothalamic and pituitary failure after successful pituitary surgery in Cushing's disease?

Authors:  A R Hermus; G F Pieters; G J Pesman; E Meijer; A G Smals; T J Benraad; P W Kloppenborg
Journal:  J Endocrinol Invest       Date:  1987-08       Impact factor: 4.256

2.  [Risk of adrenal cortex insufficiency following heart transplantation].

Authors:  M Hummel; H Warnecke; S Schüler; K Luding; R Hetzer
Journal:  Klin Wochenschr       Date:  1991-04-04

3.  Corticotropin releasing hormone in plasma of patients with Cushing's disease.

Authors:  G K Stalla; J Stalla; K von Werder; O A Müller; D K Lüdecke; U Schrell; R Fahlbusch
Journal:  Klin Wochenschr       Date:  1987-06-01

4.  Corticotropin-releasing factor induces rectal hypersensitivity after repetitive painful rectal distention in healthy humans.

Authors:  Tsukasa Nozu; Miwako Kudaira
Journal:  J Gastroenterol       Date:  2006-08       Impact factor: 7.527

5.  Lipopolysaccharide increases plasma levels of corticotropin-releasing hormone in rats.

Authors:  Miriam Goebel; Andreas Stengel; Lixin Wang; Joseph Reeve; Yvette Taché
Journal:  Neuroendocrinology       Date:  2010-12-06       Impact factor: 4.914

6.  Influences of peripheral adrenocorticotropin 1-39 (ACTH) and human corticotropin releasing hormone (h-CRH) on human auditory evoked potentials (AEP).

Authors:  J Born; B Bathelt; R Pietrowsky; P Pauschinger; H L Fehm
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

7.  CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators.

Authors:  Katherine E Wiley; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2004-09-20       Impact factor: 8.739

8.  Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome.

Authors:  S Fukudo; T Nomura; M Hongo
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

9.  The central distribution of a corticotropin-releasing factor (CRF)-binding protein predicts multiple sites and modes of interaction with CRF.

Authors:  E Potter; D P Behan; E A Linton; P J Lowry; P E Sawchenko; W W Vale
Journal:  Proc Natl Acad Sci U S A       Date:  1992-05-01       Impact factor: 11.205

10.  New effects of caffeine on corticotropin-releasing hormone (CRH)-induced stress along the intrafollicular classical hypothalamic-pituitary-adrenal (HPA) axis (CRH-R1/2, IP3 -R, ACTH, MC-R2) and the neurogenic non-HPA axis (substance P, p75NTR and TrkA) in ex vivo human male androgenetic scalp hair follicles.

Authors:  T W Fischer; A Bergmann; N Kruse; K Kleszczynski; C Skobowiat; A T Slominski; R Paus
Journal:  Br J Dermatol       Date:  2020-06-24       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.